Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model. (17th July 2014)

• Record Type: Journal Article
• Authors: Beyazyıldız, Emrullah; Pınarlı, Ferda Alpaslan; Beyazyıldız, Özlem; Hekimoğlu, Emine Rümeysa; Acar, Uğur; Demir, Muhammed Necati; Albayrak, Aynur; Kaymaz, Figen; Sobacı, Güngör; Delibaşı, Tuncay
• Other Names: Zhao Weian Academic Editor.
• Is Part Of: Stem cells international. Volume 2014(2014)
• Publication Date: 2014-07-17
• Subjects: Stem Cells -- Periodicals; Stem Cells -- Therapeutic use -- Periodicals; Stem Cells -- Transplantation -- Periodicals; 616.0277405
• DOI: 10.1155/2014/250230
• Languages: English
• ISSNs: 1687-966X

Abstract

Abstract : Purpose . The current study was set out to address the therapeutic efficacy of topically applied mesenchymal stem cells (MSCs) on dry eye syndrome (DES) induced by benzalkonium chloride (BAC) in rats. Methods . Rats were divided into two groups just after establishment of DES. Eye drops containing either bromodeoxyuridine labeled MSCs (n = 9 ) or phosphate buffer solution (n = 7 ) were topically applied once daily for one week. Schirmer test, break-up time score, ocular surface evaluation tests, and corneal inflammatory index scoring tests were applied to all rats at baseline and after treatment. All rats were sacrificed after one week for histological and electron microscopic analysis. Results . Mean aqueous tear volume and tear film stability were significantly increased in rats treated with MSCs (P < 0.05 ). Infiltration of bromodeoxyuridine labeled MSCs into the meibomian glands and conjunctival epithelium was observed in MSCs treated rats. Increased number of secretory granules and number of goblet cells were observed in MSCs treated rats. Conclusion . Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.